DNA methylation and cancer pathways in gastrointestinal tumors

Pharmacogenomics

Volumn 9, Issue 12, 2008, Pages 1917-1928

  Suzuki, Hiromu ^a   Tokino, Takashi ^a   Shinomura, Yasuhisa ^a   Imai, Kohzoh ^a   Toyota, Minoru ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

DNA methylation; gastrointestinal cancer; hypoxia; microRNA; mitotic checkpoint; p53; Ras; Wnt

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CARBOPLATIN; DNA; DNA METHYLTRANSFERASE INHIBITOR; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1; MICRORNA; PROTEIN P53; RAS PROTEIN; VALPROIC ACID; WNT PROTEIN;

ALLELE; CARCINOGENESIS; CLINICAL TRIAL; CPG ISLAND; DIGESTIVE SYSTEM CANCER; DNA METHYLATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENE SILENCING; HUMAN; MITOSIS; MYELODYSPLASTIC SYNDROME; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR SUPPRESSOR GENE; GASTROINTESTINAL TUMOR; GENETICS; METABOLISM;

DNA METHYLATION; GASTROINTESTINAL NEOPLASMS; GENE SILENCING; HUMANS; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; WNT PROTEINS;

EID: 61549121083     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.12.1917     Document Type: Review

References (123)

1. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87(2), 159-170 (1996). (Pubitemid 26358996)
2. Rashid A, Issa JP: CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 127(5), 1578-1588 (2004). (Pubitemid 39457781)
3. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
4. Takai D, Jones PA: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl Acad. Sci. USA 99(6), 3740-3745 (2002). (Pubitemid 34252176)
5. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat. Rev. Cancer 4(2), 143-153 (2004). (Pubitemid 38198742)
6. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300(5618), 455 (2003). (Pubitemid 36444319)
7. Chen RZ, Pettersson U, Beard C, Jackson- Grusby L, Jaenisch R: DNA hypomethylation leads to elevated mutation rates. Nature 395 (6697), 89-93 (1998). (Pubitemid 28420236)
8. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8(4), 286-298 (2007). (Pubitemid 46439286)
9. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat. Med. 10(8), 789-799 (2004). (Pubitemid 39070849)
10. Sjöblom T, Jones S, Wood LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268-274 (2006). (Pubitemid 44571966)
11. Wood LD, Parsons DW, Jones S et al.: The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007). (Pubitemid 350134889)
12. Schuebel KE, Chen W, Cope L et al.: Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 3(9), 1709-1723 (2007). (Pubitemid 47510263)
13. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6(2), 107-116 (2006).
14. Moon RT, Kohn AD, De Ferrari GV, Kaykas A: WNT and β-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5(9), 691-701 (2004). (Pubitemid 39150127)
15. Veeman MT, Axelrod JD, Moon RT: A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev. Cell 5(3), 367-377 (2003).
16. Esteller M, Sparks A, Toyota M et al.: Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 60(16), 4366-4371 (2000). (Pubitemid 32103613)
17. Arnold CN, Goel A, Niedzwiecki D et al.: APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol. Ther. 3(10), 960-964 (2004). (Pubitemid 41351019)
18. Tsuchiya T, Tamura G, Sato K et al.: Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene 19(32), 3642-3646 (2000). (Pubitemid 30608485)
19. Takeichi, M: Morphogenetic roles of classic cadherins. Curr. Opin. Cell Biol. 7(5), 619-627 (1995).
20. Fodde R, Smits R, Clevers H: APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1(1), 55-67 (2001). (Pubitemid 33741881)
21. Nelson WJ, Nusse R: Convergence of Wnt, β-catenin, and cadherin pathways. Science 303(5663), 1483-1487 (2004). (Pubitemid 38314410)
22. Eads CA, Lord RV, Kurumboor SK et al.: Fields of aberrant CpG island hypermethylation in Barretts esophagus and associated adenocarcinoma. Cancer Res. 60(18), 5021-5026 (2000).
23. Suzuki H, Itoh F, Toyota M et al.: Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int. J. Cancer 83(3), 309-313 (1999). (Pubitemid 29455752)
24. Tamura G, Yin J, Wang S et al.: E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J. Natl. Cancer Inst. 92(7), 569-573 (2000). (Pubitemid 30212319)
25. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasionsuppressor gene by CpG methylation in human carcinomas. Proc. Natl Acad. Sci. USA 92(16), 7416-7419 (1995). (Pubitemid 27224296)
26. Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ, Bodmer WF: Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut 48(3), 367-371 (2001). (Pubitemid 32269565)
27. Kanai Y, Ushijima S, Hui AM et al.: The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int. J. Cancer 71(3), 355-359 (1997). (Pubitemid 27224296)
28. Guilford P, Hopkins J, Harraway J et al.: E-cadherin germline mutations in familial gastric cancer. Nature 392(6674), 402-405 (1998). (Pubitemid 28168738)
29. Grady WM, Willis J, Guilford PJ et al.: Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat. Genet. 26(1), 16-17 (2000). n First report to show that DNA methylation plays a role as the second hit in hereditary gastric cancer.
30. Kawano Y, Kypta R: Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 116(Pt 13), 2627-2634 (2003). (Pubitemid 36857216)
31. Jones SE, Jomary C: Secreted frizzled-related proteins: searching for relationships and patterns. Bioessays 24(9), 811-820 (2002). (Pubitemid 35022186)
32. Suzuki H, Gabrielson E, Chen W et al.: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31(2), 141-149 (2002).
33. Suzuki H, Watkins DN, Jair KW et al.: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36(4), 417-422 (2004). (Pubitemid 38437267)
34. Nojima M, Suzuki H, Toyota M et al.: Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 26(32), 4699-4713 (2007). (Pubitemid 47067406)
35. Shih YL, Shyu RY, Hsieh CB et al.: Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer 107(3), 579-590 (2006).
36. Takagi H, Sasaki S, Suzuki H et al.: Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J. Gastroenterol. 43(5), 378-389 (2008). (Pubitemid 351958902)
37. Sato N, Fukushima N, Maitra A et al.: Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 63(13), 3735-3742 (2003). (Pubitemid 36793060)
38. Sogabe Y, Suzuki H, Toyota M et al.: Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int. J. Oncol. 32(6), 1253-1261 (2008). (Pubitemid 351958902)
39. Shih YL, Hsieh CB, Lai HC et al.: SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int. J. Cancer 121(5), 1028-1035 (2007).
40. Pinto D, Gregorieff A, Begthel H, Clevers H: Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev. 17(14), 1709-1713 (2003). (Pubitemid 36870334)
41. Kuhnert F, Davis CR, Wang HT et al.: Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc. Natl Acad. Sci. USA 101(1), 266-271 (2004). (Pubitemid 38084239)
42. Niehrs C: Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25(57), 7469-7481 (2006). (Pubitemid 44885746)
43. Mikheev AM, Mikheeva SA, Liu B, Cohen P, Zarbl H: A functional genomics approach for the identification of putative tumor suppressor genes, Dickkopf-1 as suppressor of HeLa cell transformation. Carcinogenesis 25(1), 47-59 (2004). (Pubitemid 38128618)
44. Niida A, Hiroko T, Kasai M et al.: DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway. Oncogene 23(52), 8520-8526 (2004). (Pubitemid 39540802)
45. Gonzélez-Sancho JM, Aguilera O, Garca JM et al.: The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/ TCF and is downregulated in human colon cancer. Oncogene 24(6), 1098-1103 (2005). (Pubitemid 40313887)
46. Aguilera O, Fraga MF, Ballestar E et al.: Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25(29), 4116-4121 (2006). (Pubitemid 44024874)
47. Sato H, Suzuki H, Toyota M et al.: Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 28(12), 2459-2466 (2007). (Pubitemid 350238947)
48. Mazieres J, He B, You L et al.: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 64(14), 4717-4720 (2004). (Pubitemid 38924512)
49. Taniguchi H, Yamamoto H, Hirata T et al.: Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24(53), 7946-7952 (2005). (Pubitemid 41715201)
50. Zhang W, Glöckner SC, Guo M et al.: Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 68(8), 2764-2772 (2008). (Pubitemid 351556274)
51. Sinner D, Kordich JJ, Spence JR et al.: Sox17 and Sox4 differentially regulate β-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol. Cell. Biol. 27(22), 7802-7815 (2007). (Pubitemid 350086414)
52. Yuasa Y: Control of gut differentiation and intestinal-type gastric Carcinogenesis. Nat. Rev. Cancer 3(8), 592-600 (2003). (Pubitemid 37328831)
53. Malumbres M, Barbacid M: RAS Oncogenes: the first 30 years. Nat. Rev. Cancer 3(6), 459-465 (2003). (Pubitemid 37328850)
54. Tuveson DA, Weber BL, Herlyn M: BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4(2), 95-98 (2003). (Pubitemid 37040825)
55. Rajagopalan H, Bardelli A, Lengauer C et al.: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418(6901), 934 (2002). (Pubitemid 34976022)
56. Campisi J: Suppressing cancer: the importance of being senescent. Science 309(5736), 886-887 (2005). (Pubitemid 41099913)
57. Mooi WJ, Peeper DS: Oncogene-induced cell senescence-halting on the road to cancer. N. Engl. J. Med. 355(10), 1037-1046 (2006).
58. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25(3), 315-319 (2000). (Pubitemid 30437320)
59. van Engeland M, Roemen GM, Brink M et al.: K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21(23), 3792-3795 (2002). (Pubitemid 34620542)
60. Akino K, Toyota M, Suzuki H et al.: The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 129(1), 156-169 (2005). (Pubitemid 41002052)
61. Tommasi S, Dammann R, Jin SG, Zhang XF, Avruch J, Pfeifer GP: RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 21(17), 2713-2720 (2002). (Pubitemid 34478329)
62. Allen NP, Donninger H, Vos MD et al.: RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 26(42), 6203-6211 (2007). (Pubitemid 47414375)
63. Falvella FS, Manenti G, Spinola M et al.: Identification of RASSF8 as a candidate lung tumor suppressor gene. Oncogene 25(28), 3934-3938 (2006). (Pubitemid 43990748)
64. Nosho K, Yamamoto H, Takahashi T et al.: Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis 28(6), 1364-1370 (2007). (Pubitemid 47062698)
65. Endoh M, Tamura G, Honda T et al.: RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br. J. Cancer 93(12), 1395-1399 (2005). (Pubitemid 41752867)
66. Maruyama R, Akino K, Toyota M et al.: Cytoplasmic RASSF2A is a pro-apoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 29(7), 1312-1318 (2008).
67. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253(5015), 49-53 (1991). (Pubitemid 21917115)
68. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 408(6810), 307-310 (2000).
69. Esteller M, Tortola S, Toyota M et al.: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 60(1), 129-133 (2000). (Pubitemid 30058742)
70. Esteller M, Cordon-Cardo C, Corn PG et al.: p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res. 61(7), 2816-2821 (2001). (Pubitemid 32691917)
71. Iida S, Akiyama Y, Nakajima T et al.: Alterations and hypermethylation of the p14 (ARF) gene in gastric cancer. Int. J. Cancer 87(5), 654-658 (2000). (Pubitemid 30620407)
72. Shen L, Kondo Y, Hamilton SR, Rashid A, Issa JP: P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology 124(3), 626-633 (2003). (Pubitemid 36268481)
73. Hermeking H, Lengauer C, Polyak K et al.: 14-3-3δ is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1(1), 3-11 (1997). (Pubitemid 127376388)
74. Ferguson AT, Evron E, Umbricht CB et al.: High frequency of hypermethylation at the 14-3-3δ locus leads to gene silencing in breast cancer. Proc. Natl Acad. Sci. USA 97(11), 6049-6054 (2000). (Pubitemid 30367521)
75. Gasco M, Bell AK, Heath V et al.: Epigenetic inactivation of 14-3-3δ in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res. 62(7), 2072-2076 (2002). (Pubitemid 34408454)
76. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K: Inactivation of the 14-3-3δ gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res. 60(16), 4353-4357 (2000). (Pubitemid 32103610)
77. Iwata N, Yamamoto H, Sasaki S et al.: Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3δ gene in human hepatocellular carcinoma. Oncogene 19(46), 5298-5302 (2000).
78. Osada H, Tatematsu Y, Yatabe Y et al.: Frequent and histological type-specific inactivation of 14-3-3δ in human lung cancers. Oncogene 21(15), 2418-2424 (2002). (Pubitemid 34407301)
79. Akino K, Toyota M, Suzuki H et al.: Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci. 98(1), 88-95 (2007). (Pubitemid 44803925)
80. Masuda Y, Futamura M, Kamino H et al.: The potential role of DFNA5, a hearing impairment gene, in p53-mediated cellular response to DNA damage. J. Hum. Genet. 51(8), 652-664 (2006). (Pubitemid 44354677)
81. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6(4), 259-269 (2006).
82. He L, He X, Lim LP et al.: A microRNA component of the p53 tumour suppressor network. Nature 447(7148), 1130-1134 (2007). (Pubitemid 47014436)
83. Bommer GT, Gerin I, Feng Y et al.: p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17(15), 1298-1307 (2007). (Pubitemid 47176893)
84. Chang TC, Wentzel EA, Kent OA et al.: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26(5), 745-752 (2007).
85. Raver-Shapira N, Marciano E, Meiri E et al.: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26(5), 731-743 (2007). (Pubitemid 46856247)
86. Tarasov V, Jung P, Verdoodt B et al.: Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6(13), 1586-1593 (2007). (Pubitemid 47327945)
87. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H: Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl Acad. Sci. USA 104(39), 15472-15477 (2007). (Pubitemid 47502941)
88. Toyota M, Suzuki H, Sasaki Y et al.: Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 68(11), 4123-4132 (2008).
89. Lujambio A, Calin GA, Villanueva A et al.: A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. Sci. USA 105(36), 13556-13561 (2008).
90. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 68(7), 2094-2105 (2008). (Pubitemid 351521781)
91. Semenza GL: Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5(5), 405-406 (2004).
92. Michiels C: Physiological and pathological responses to hypoxia. Am. J. Pathol. 164(6), 1875-1882 (2004). (Pubitemid 38669336)
93. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL: HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61(18), 6669-6673 (2001). (Pubitemid 32896483)
94. Greijer AE, van der Wall E: The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J. Clin. Pathol. 57(10), 1009-1014 (2004). (Pubitemid 39331346)
95. Bruick RK: Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl Acad. Sci. USA 97(16), 9082-9087 (2000). (Pubitemid 30626677)
96. Sowter HM, Ferguson M, Pym C et al.: Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. J. Pathol. 201(4), 573-580 (2003). (Pubitemid 38256406)
97. Murai M, Toyota M, Suzuki H et al.: Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin. Cancer Res. 11(3), 1021-1027 (2005). (Pubitemid 40175749)
98. Okami J, Simeone DM, Logsdon CD: Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res. 64(15), 5338-5346 (2004). (Pubitemid 39006554)
99. Abe T, Toyota M, Suzuki H et al.: Upregulation of BNIP3 by 5-aza-2′- deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J. Gastroenterol. 40(5), 504-510 (2005). (Pubitemid 40823286)
100. Jallepalli PV, Lengauer C: Chromosome segregation and cancer: cutting through the mystery. Nat. Rev. Cancer 1(2), 109-117 (2001). (Pubitemid 33741886)
101. Scolnick DM, Halazonetis TD: Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406(6794), 430-435 (2000).
102. Toyota M, Sasaki Y, Satoh A et al.: Epigenetic inactivation of CHFR in human tumors. Proc. Natl Acad. Sci. USA 100(13), 7818-7823 (2003). (Pubitemid 36760053)
103. Satoh A, Toyota M, Itoh F et al.: Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 63(24), 8606-8613 (2003). (Pubitemid 38064034)
104. Honda T, Tamura G, Waki T, Kawata S, Nishizuka S, Motoyama T: Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia. Br. J. Cancer 90(10), 2013-2016 (2004). (Pubitemid 38746346)
105. Ogi K, Toyota M, Mita H et al.: Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol. Ther. 4(7), 773-780 (2005). (Pubitemid 41351179)
106. Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6(4), 321-330 (2006).
107. Anand S, Penrhyn-Lowe S, Venkitaraman AR: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell 3(1), 51-62 (2003). (Pubitemid 37443890)
108. Yu X, Minter-Dykhouse K, Malureanu L et al.: Chfr is required for tumor suppression and Aurora A regulation. Nat. Genet. 37(4), 401-406 (2005). (Pubitemid 40490490)
109. Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K: The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J. Gastroenterol. 41(2), 133-139 (2006).
110. Linhart HG, Lin H, Yamada Y et al.: Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev. 21(23), 3110-3122 (2007). (Pubitemid 350223528)
111. Lee TI, Jenner RG, Boyer LA et al.: Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125(2), 301-313 (2006). (Pubitemid 44313811)
112. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K: Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20(9), 1123-1136 (2006).
113. Widschwendter M, Fiegl H, Egle D et al.: Epigenetic stem cell signature in cancer. Nat. Genet. 39(2), 157-158 (2007). (Pubitemid 46184343)
114. Schlesinger Y, Straussman R, Keshet I et al.: Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39(2), 232-236 (2007). (Pubitemid 46184355)
115. Ohm JE, McGarvey KM, Yu X et al.: A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39(2), 237-242 (2007). (Pubitemid 46184356)
116. Issa JP: DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 13(6), 1634-1637 (2007). (Pubitemid 46952927)
117. Zelent A, Petrie K, Boix-Chornet M, Melnick AM, Waxman S, Gore SD: Derepression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics. Cancer Res. 68(13), 4967-4970 (2008).
118. Morita S, Iida S, Kato K, Takagi Y, Uetake H, Sugihara K: The synergistic effect of 5-aza-2′-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology 71(5-6), 437-445 (2006).
119. Zhang X, Yashiro M, Ohira M, Ren J, Hirakawa K: Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Sci. 97(9), 938-944 (2006). (Pubitemid 44151277)
120. Appleton K, Mackay HJ, Judson I et al.: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25(29), 4603-4609 (2007). (Pubitemid 350035319)
121. Braiteh F, Soriano AO, Garcia-Manero G et al.: Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res. 14(19), 6296-6301 (2008).
122. Shen L, Toyota M, Kondo Y et al.: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104(47), 18654-18659 (2007). (Pubitemid 350210752)
123. Nagasaka T, Koi M, Kloor M et al.: Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 134(7), 1950-1960 (2008). (Pubitemid 351790743)